Virtual Library

Start Your Search

Jorge Martinalbo

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice (ID 227)

      12:30 - 13:00  |  Author(s): Jorge Martinalbo

      • Abstract
      • Slides


      In the randomised Ph III OAK study, atezo (anti–PD-L1) significantly improved survival vs docetaxel, regardless of PD-L1 levels, and was approved by the FDA and EMA as 2L+ tx for advanced NSCLC. Given limited real-world data (RWD) on atezo in clinical practice, we describe here tx and characteristics of pts receiving atezo in clinical practice.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Pts diagnosed with advanced NSCLC on or after Jan 1, 2011, and who initiated 2L+ atezo before Jul 1, 2017, were identified from the Flatiron Health database of electronic health records from US-based hospitals and community practices. Time-on-treatment (TOT) was defined as time from first to last atezo dose, plus 1 cycle. Median TOT was calculated using the Kaplan-Meier methods. Data from the OAK registrational trial (NCT02008227) are provided.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      122 pts met selection criteria (Table). 105 pts (86%) had 2L+ atezo without prior anti–PD-1 tx, while 17 pts (14%) had prior anti–PD-1 tx. Median TOT was 3.9 mo (95% CI: 2.9, 4.9), similar to OAK. A median of 4 cycles was administered for both non-squamous (IQR 1-22) and squamous (IQR 1-17) histology. Progression was the most common reason for atezo discontinuation.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      TOT with atezo in the US RW setting was similar to the OAK clinical trial setting, although pts treated in RW were older and 22% had ≥ 3 lines of previous therapy.

      b651e8a99c4375feb982b7c2cad376e9 Editorial acknowledgement

      Medical writing assistance for this abstract was provided by Steffen Biechele, PhD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.

      934ce5ff971f1ab29e840a35e3ca96e9 Legal entity responsible for the study

      F. Hoffmann-La Roche, Ltd.

      213f68309caaa4ccc14d5f99789640ad Funding

      F. Hoffmann-La Roche, Ltd.

      682889d0a1d3b50267a69346a750433d Disclosure

      M. Frueh: Consulting/advisory: BMS, MSD, AZ, BI, Roche; Research funding: MSD. O.E. Rahma: Advisory board: Celgene, Leerink, PRMA Couns., Outcomes4me, Puretech; Consulting: Alcimed SAS, GFK, Merck, Five Prime, Defined Health Honorarium: Merck, Clinical Care Option, Mi Bioresearch, Alaunusglobal; Other (study/editorial support): Roche. R.K. Pachynski: Grants/research support: Ferring, Janssen; Consultant: AZ, BMS, EMD Serono, Exelixis, Dendreon, Jounce, Pfizer; Speakers: AZ, GNE/Roche, Dendreon, Genomic Health, Sanofi, Merck; Other (support of parent study and funding of editorial support): Roche. J. Mazieres: Financial relationship: Roche, BMS, MSD, AstraZeneca, Pfizer, Novartis: consulting fees; Contracted research: Roche, BMS. J. Goldschmidt Jr.: Consulting/advisory role/honorarium: Amgen; Speakers bureau: BMS, Celgene; Support of parent study, funding of editorial support: Roche. T.G.N. Ton: Full time employee with self-managed stock: Genentech/Roche. S.K. Mhatre: Genentech, Inc./F. Hoffmann-La Roche: full time employee F. Hoffmann-La Roche: Stock shareholder (self managed) C-Y. Chuo: Full time employee, stock, support of parent study, funding of editorial support: Roche/Genentech. J. Martinalbo, J. Davies: Full time employee: F. Hoffmann-La Roche. R. Juergens: Honoraria: Amgen, AZ, BI, BMS, Lilly, Merck Sharp & Dohme, Roche Canada; Consulting or advisory role: Amgen, AZ, BI, BMS, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche Canada; Research funding: AZ/MedImmune, BMS, Merck Sharp & Dohme, Novartis.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.